Communiqués HCW Biologics Inc.

Actions

HCWB

US40423R1059

Marché Fermé - Nasdaq Autres places de cotation 22:30:01 01/07/2024			Varia. 5j.	Varia. 1 janv.
0,65 ^USD	+0,46%		-18,77%	-46,94%

15/05	HCW Biologics Inc. déclare ses résultats pour le premier trimestre clos le 31 mars 2024	CI
01/04	HCW Biologics Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights	15/05	AQ
HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights	01/04	AQ
HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights	14/11	AQ
Investigator Sponsor of HCW Biologics’ Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting	08/11	GL
HCW Biologics : First-in-Human Clinical Readout of HCW9218, SITC 2023	06/11	PU
Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual Meeting	01/11	GL
HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023	06/09/23	GL
HCW Biologics Reports Second Quarter 2023 Financial Results and Recent Business Highlights	11/08/23	AQ
HCW Biologics is Granted Third Fundamental Patent: U.S. Patent for Methods of Treating Age-Related Disorders	14/06/23	AQ
HCW BIOLOGICS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	09/05/23	AQ
HCW BIOLOGICS INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)	09/05/23	AQ
HCW Biologics Reports First Quarter 2023 Financial Results And Recent Business Highlights	09/05/23	AQ
HCW Biologics Secures $26.25 Million Non-Dilutive Financing With Asset-Backed Development Loan	27/04/23	GL
HCW Biologics Secures $26.25 Million Non-Dilutive Financing With Asset-Backed Development Loan	27/04/23	AQ
HCW BIOLOGICS INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits (form 8-K)	27/04/23	AQ
HCW Biologics Poster Presentation at AACR Annual Meeting 2023	13/04/23	AQ
A Novel Immunotherapeutic Approach to Treating Aging-Associated Diseases	03/04/23	AQ
HCW BIOLOGICS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	28/03/23	AQ
HCW BIOLOGICS INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)	28/03/23	AQ
HCW Biologics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights	28/03/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués HCW Biologics Inc.

Actions

HCWB

US40423R1059

Communiqués

Filtres